Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background Cardiovascular disease (CVD) is one of the leading causes of death in Belgium. Current strategies for the prevention and management of CVD focus on reducing low-density lipoprotein cholesterol (LDL-C) levels. This analysis assessed whether LDL-C goals, recommended by the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines, were being achieved in a Belgian study population.Methods The cross-sectional, observational, DA VINCI study enrolled patients prescribed lipid-lowering therapy (LLT) between 21 June 2017 and 20 November 2018. Data for patients from Belgium were extracted for this country-specific analysis. Primary endpoint was the proportion of patients who achieved 2016 ESC/EAS risk-based LDL-C goals; attainment of 2019 risk-based LDL-C goals was evaluated post hoc.Results Of 497 enrolled patients, 41% were female and mean age was 68 years. Among subjects with an LDL-C measurement on stabilised LLT, moderate-intensity statin monotherapy was the most prescribed LLT regimen (59%). Overall, 63% of patients achieved their risk-based LDL-C goals according to the 2016 ESC/EAS guidelines. Among patients with established ASCVD, risk-based LDL-C goal attainment was higher in patients with peripheral arterial disease (53%) than patients with coronary (37%) and cerebrovascular disease (42%). According to the updated 2019 ESC/EAS guidelines, less than half (41%) of patients achieved their risk-based LDL-C goal. The proportion of primary and secondary prevention patients who achieved 2019 risk-based LDL-C goals was 59% and 18%, respectively.Conclusion These findings reveal a large gap between the LDL-C goals advocated by the ESC/EAS and the levels achieved in routine clinical practice in Belgium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results were consistent across European countries [13–15].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 1×
“Randomised clinical trials and real-world evidence have shown that the reduction of LDL-C levels using lipid-lowering therapies (LLT) reduces the risk of CVD [4 – 7].”
BackgroundEstimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290 · cited 1×
“For this subset, the 10-year risk of fatal CVD was calculated using the Systematic Coronary Risk Evaluation (SCORE) [19] and estimated glomerular filtration rate (eGFR) at LDL-C measurement.”
MethodEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · cited 1×
“The merits of attaining LDL-C levels of around 53 mg/dL compared to 70 mg/dl in very high-risk patients were shown in the IMPROVE-IT study [21].”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Leon, B. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i13.1246 · Cited by 1,215
Kotseva, K., De Backer, G., De Bacquer, D., Rydén, L., Hoes, A., Grobbee, D., Maggioni, A., Marques-Vidal, P., Jennings, C., Abreu, A., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318825350 · Cited by 937 · cited 1×
“Similarly, the EUROASPIRE V survey, which interviewed 8261 patients with coronary artery disease across 27 European countries, found that most patients did not achieve their LDL-C goals [11].”
Background
Research works printed but not linked: 2
- Herink M Ito MK. Medication induced changes in lipid and lipoproteins [updated 2018 May 10]. In: Feingold KR Anawalt B Boyce A et al. editors. Endotext [Internet]. South Dartmouth (MA): MDText.com Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326739/
- Goossens M, Kalyvas C, Kennel T, et al. De zorgtrajecten diabetes mellitus type 2 en chronische nierinsufficiëntie en kwaliteit van zorg. Brussel: Sciensano. Depotnummer; 2017–2019.
Cited by
Palaniappan, L. P., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 242
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
Biolo, G., Vinci, P., Mangogna, A., Landolfo, M., Schincariol, P., Fiotti, N., Mearelli, F., & Girolamo, F. G. D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1028355 · Cited by 85
Biomarkers and inflammation in coronary artery disease: key insights
Lancellotti, P., & Bonardeaux, O. D. L. B. (2024) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2024.2421090 · Cited by 15
Focus on cardiometabolic risk factors
Lancellotti, P. (2023) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2231702 · Cited by 15
Metadata
- Authors
- van de Borne, P., Peeters, A., Janssens, L., Leone, A., Lemmens, R., Verhaegen, A., De Meulemeester, M., Balthazar, Y., Heijmans, S., Calozet, Y., Paquot, N., Carlier, S., Hemelsoet, D., Bray, S., & Ray, K. K.
- Affiliations
- Department of Cardiology, Erasme Hospital, University Libre of Brussels, Brussels, Belgium
- Department of Neurology, Saint Luc University Clinic, Brussels, Belgium
- Imelda Hospital (BE)
- Centre Hospitalier Universitaire de Tivoli (BE)
- KU Leuven (BE)
- Antwerp University Hospital (BE)
- GP, Private Practice, Gozée, Belgium
- GP, Private Practice, Natoye, Belgium
- GP, Private Practice, Linkebeek, Belgium
- GP, Private Practice, Gribomont, Belgium
- Centre Hospitalier Universitaire de Liège (BE)
- Department of Cardiology, Ambroise Paré Hospital and University of Mons (UMONS), Mons, Belgium
- Ghent University Hospital (BE)
- Amgen (United Kingdom) (GB)
- Imperial College London (GB)
- ORCID
- Venue
- Acta Cardiologica
- Publisher
- Informa UK Limited
- Published
- 2022-04-20
- Volume
- 79
- Issue
- 1
- Pages
- 20-29
- ISSN
- 0373-7934 (ISSN-L)
- 0001-5385
- OpenAlex
- W4224240316
- Semantic Scholar
- 849a7ab120e493dea9bb950c5eb14525f17ffc3f
- Cited by
- 22
- References
- 26
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 5 · 2023: 6 · 2022: 1
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Acta cardiologica. Supplementum (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
- Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
- ORBi UMONS (submittedVersion, cc-by-nc-nd)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- Amgen GmbH
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- lipid-lowering therapy, LDL cholesterol targets, ESC/EAS guidelines, statin monotherapy, guideline adherence, peripheral arterial disease, primary and secondary prevention, cardiovascular disease prevention, Belgium
- MeSH terms
- Aged, Belgium, Cardiovascular Diseases, Cross-Sectional Studies, Female, Goals, Humans, Cholesterol, LDL, Male, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Atherosclerosis, Peripheral Arterial Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. https://app.cochat.ai/papers/10.1080/00015385.2022.2030568
- The paper
- van de Borne, P., Peeters, A., Janssens, L., Leone, A., Lemmens, R., Verhaegen, A., De Meulemeester, M., Balthazar, Y., Heijmans, S., Calozet, Y., Paquot, N., Carlier, S., Hemelsoet, D., Bray, S., & Ray, K. K. (2024). Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. Acta Cardiologica. https://doi.org/10.1080/00015385.2022.2030568
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.